Oral Malignant Neoplasms

Oral malignant neoplasms encompass a diverse group of aggressive tumors arising from the epithelial, mesenchymal, or melanocytic tissues of the oral cavity, including the lips, gingiva, tongue, hard and soft palate, buccal mucosa, and tonsils. These tumors are characterized by local invasiveness, potential for regional lymph node metastasis, and variable distant dissemination. In veterinary surgical oncology, the most common oral malignancies in dogs are malignant melanoma, squamous cell carcinoma (SCC), and fibrosarcoma, while in cats, SCC predominates. Surgical management is the cornerstone of therapy, often combined with adjunctive treatments such as radiation therapy, chemotherapy, or immunotherapy. The surgical approach requires meticulous preoperative staging, wide en bloc resection with histologically confirmed clean margins, and reconstruction of the resulting defect to maintain function and cosmesis. The prognosis is highly dependent on tumor type, location, stage, and completeness of excision.

The exact etiology of oral malignant neoplasms is multifactorial and not fully understood. For squamous cell carcinoma, chronic inflammation, exposure to environmental carcinogens (e.g., tobacco smoke, dietary factors), and viral agents (e.g., papillomavirus) have been implicated. In cats, chronic stomatitis and possibly retroviral infections (FeLV, FIV) may predispose to SCC. Malignant melanoma arises from melanocytes, with genetic predisposition and ultraviolet radiation (in unpigmented oral mucosa) as potential triggers. Fibrosarcoma may be associated with chronic inflammation, trauma, or prior radiation exposure. Other factors include genetic mutations (e.g., p53, RAS), chromosomal aberrations, and dysregulation of growth factors. In dogs, certain breeds have a higher incidence, suggesting a hereditary component. The oral cavity's rich vascular and lymphatic supply facilitates rapid growth and metastasis.

Oral malignant neoplasms account for approximately 6% of all canine tumors and 3% of feline tumors. In dogs, malignant melanoma is the most common (30-40% of oral malignancies), followed by SCC (25-30%) and fibrosarcoma (10-20%). These tumors typically affect older dogs (median age 10-12 years), with no strong sex predilection. Breeds at increased risk for melanoma include Scottish Terriers, Golden Retrievers, and Poodles; SCC is more common in Beagles, Bloodhounds, and Gordon Setters; fibrosarcoma is seen in large breeds such as Golden Retrievers and Doberman Pinschers. In cats, SCC is the most frequent oral malignancy (70-80%), with a median age of 12 years, and no breed predilection, though Siamese and Persian cats may be overrepresented. Oral tumors are rare in young animals, but when present, they are often more aggressive.

Oral malignant neoplasms arise from uncontrolled cellular proliferation of oral mucosal or submucosal tissues. Tumor growth is driven by genetic mutations that activate oncogenes or inactivate tumor suppressor genes, leading to evasion of apoptosis, sustained angiogenesis, and tissue invasion. Malignant melanoma originates from melanocytes in the basal layer of the oral epithelium, often on the gingiva or mucosa, and is highly invasive, with early metastasis to regional lymph nodes (mandibular, retropharyngeal) and lungs. Squamous cell carcinoma arises from keratinocytes of the oral squamous epithelium, with a tendency to invade underlying bone, especially in the mandible or maxilla. Fibrosarcoma originates from fibroblasts in the submucosa, is locally aggressive with a high recurrence rate, but metastasizes less frequently. Tumor growth causes mechanical disruption of normal oral structures, leading to pain, dysphagia, excessive salivation, and weight loss. Local invasion of bone results in osteolysis and pathological fractures. Metastasis occurs via lymphatic and hematogenous routes, with the lungs being the most common distant site.

Intrinsic factors include age (older animals), breed-specific genetic susceptibility, and immune status. Chronic oral inflammation, such as periodontitis or stomatitis, may predispose to SCC. Extrinsic factors include exposure to environmental carcinogens (e.g., tobacco smoke, certain chemicals), dietary factors (e.g., high-fat diets), and possibly viral infections (papillomavirus in dogs, FeLV/FIV in cats). Prior radiation therapy to the head and neck region is a risk factor for secondary malignancies. Poor oral hygiene and dental disease may contribute to chronic irritation. In cats, the use of flea collars and exposure to environmental tobacco smoke have been associated with an increased risk of oral SCC.

Clinical signs vary depending on tumor location, size, and stage. Common signs include a visible oral mass, halitosis, ptyalism (excessive drooling), dysphagia, anorexia, weight loss, oral bleeding, loose teeth, facial swelling, and pain on opening the mouth. Tumors on the tongue may cause difficulty prehending food, while tonsillar SCC can present with cervical lymphadenopathy and tonsillar asymmetry. Advanced tumors may cause exophthalmos, nasal discharge, or pathological fractures of the mandible or maxilla. On physical examination, the tumor may be ulcerated, necrotic, or friable. Regional lymph nodes (mandibular, retropharyngeal) may be enlarged and firm. Systemic signs such as lethargy and fever may occur with secondary infection or metastasis.

Differential diagnoses include benign oral tumors (e.g., epulis, fibroma, papilloma), inflammatory lesions (e.g., eosinophilic granuloma, pyogenic granuloma), odontogenic tumors (e.g., ameloblastoma, odontoma), and non-neoplastic conditions such as abscesses, cysts, and foreign body reactions. Specific differentials: 1) Epulis (peripheral odontogenic fibroma) - benign, slow-growing, often on gingiva, no bone invasion on radiographs. 2) Oral papillomatosis - viral, cauliflower-like, multiple, often in young dogs. 3) Eosinophilic granuloma complex (cats) - ulcerative lesions on lips or tongue, responsive to corticosteroids. 4) Osteomyelitis - bone lysis with periosteal reaction, history of trauma or dental disease, responds to antibiotics. 5) Ameloblastoma - benign but locally invasive, often cystic on imaging. 6) Squamous cell carcinoma (SCC) - malignant, invasive, may be indistinguishable from other malignancies without biopsy. 7) Fibrosarcoma - locally aggressive, may have a firm, lobulated appearance. 8) Malignant melanoma - often pigmented, but can be amelanotic, highly metastatic. 9) Lymphoma - may present as a soft tissue mass, often with systemic signs. 10) Metastatic tumors - rare, but consider primary tumors elsewhere.

The diagnostic workup follows a systematic approach: 1) Complete history and thorough physical examination, including oral cavity inspection and palpation of regional lymph nodes. 2) Fine-needle aspiration (FNA) of the oral mass and any enlarged lymph nodes for cytology. 3) Three-view thoracic radiography (or CT) to screen for pulmonary metastasis. 4) Advanced imaging of the head: computed tomography (CT) is preferred for assessing bone invasion, tumor extent, and lymph node involvement; magnetic resonance imaging (MRI) may be used for soft tissue detail. 5) Incisional biopsy (or excisional biopsy for small tumors) for histopathology and immunohistochemistry (e.g., Melan-A for melanoma, cytokeratin for carcinoma). 6) Staging based on the TNM system (Tumor, Node, Metastasis) to guide treatment and prognosis. 7) Consider sentinel lymph node mapping and biopsy for accurate nodal staging. 8) Baseline bloodwork (CBC, biochemistry, urinalysis) and coagulation profile for surgical planning.

Complete blood count (CBC) may reveal anemia due to chronic blood loss or inflammation, and leukocytosis with a left shift if secondary infection is present. Serum biochemistry may show elevated globulins (chronic inflammation) and, in advanced cases, hypercalcemia (paraneoplastic syndrome, especially in SCC). Liver and kidney values are important for anesthetic and chemotherapeutic drug dosing. Urinalysis is routine. Coagulation panel (PT, aPTT, platelet count) is recommended to assess surgical bleeding risk, especially for extensive resections. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated. Cytology of FNA samples can provide a preliminary diagnosis, but histopathology is definitive. Immunohistochemistry (IHC) is often needed to differentiate tumor types (e.g., Melan-A, PNL2 for melanoma; cytokeratin for carcinoma; vimentin for sarcoma).

Radiography: Intraoral radiographs or dental radiographs can reveal bone lysis, periosteal reaction, or tooth root resorption. Thoracic radiographs (three views) are essential for detecting pulmonary metastases, which appear as well-defined nodules. CT: Provides detailed assessment of tumor size, extent, bone invasion, and involvement of adjacent structures (e.g., nasal cavity, orbit). CT is superior to radiography for surgical planning and is recommended for all oral malignancies. MRI: Offers excellent soft tissue contrast, useful for evaluating tongue, palate, or tonsillar tumors, and for assessing perineural invasion. Ultrasonography: May be used to evaluate cervical lymph nodes and guide FNA. Scintigraphy or PET-CT may be used in specialized centers for staging. Angiography or fluoroscopy is rarely needed but may be used for vascular mapping in complex reconstructions.

Cytology: FNA of oral masses often yields cells with malignant features (e.g., anisocytosis, anisokaryosis, prominent nucleoli). Melanoma cells may contain melanin granules, but amelanotic melanomas require IHC. SCC shows keratin pearls and intercellular bridges. Fibrosarcoma shows spindle cells with high cellularity. Cytology of lymph nodes can detect metastasis. Histopathology: Incisional biopsy is the gold standard. Tumor type, grade, and surgical margins are assessed. For melanoma, IHC for Melan-A and PNL2 is positive. SCC is positive for cytokeratin. Fibrosarcoma is positive for vimentin. Histologic grading (e.g., degree of differentiation, mitotic index) correlates with prognosis. Surgical margins are evaluated for tumor-free status; a margin of at least 1 cm is recommended. Special stains (e.g., Masson's trichrome for collagen) may be used.

Treatment is primarily surgical, with the goal of complete excision with clean margins. Preoperative stabilization includes pain management, nutritional support (feeding tube if dysphagia), and treatment of secondary infections. Surgical options depend on tumor location and size: 1) Marginal resection for small, superficial tumors (e.g., epulis) but not recommended for malignant tumors. 2) Wide local excision (1-2 cm margins) for tumors not involving bone. 3) Mandibulectomy (partial, segmental, or hemimandibulectomy) for mandibular tumors. 4) Maxillectomy (partial or subtotal) for maxillary tumors. 5) Glossectomy (partial or total) for tongue tumors. 6) Tonsillectomy for tonsillar SCC. Surgical approaches follow standard oral surgery techniques. Reconstruction may involve primary closure, local flaps (e.g., buccal mucosal flap), or skin grafts. Suture materials: absorbable monofilament (e.g., polydioxanone, 3-0 or 4-0) for mucosal closure. Implants: plates and screws for mandibular reconstruction if needed. Intraoperative complications include hemorrhage, which can be controlled with electrocautery, ligation, or packing. Postoperative pain management is crucial: opioids (e.g., hydromorphone 0.05-0.1 mg/kg IV q4-6h), NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h), and local blocks (e.g., bupivacaine 1-2 mg/kg). Adjunctive therapy: Radiation therapy is effective for melanoma, SCC, and fibrosarcoma, especially with incomplete margins. Chemotherapy (e.g., carboplatin for melanoma, mitoxantrone for SCC) may be used for metastatic disease. Immunotherapy (e.g., Oncept melanoma vaccine) is available for canine melanoma. Physical rehabilitation may include feeding adjustments and oral hygiene.

Prognosis varies by tumor type and stage. For canine malignant melanoma, median survival time (MST) with surgery alone is 5-6 months; with surgery and radiation, MST is 12-18 months; with Oncept vaccine, MST may exceed 2 years. For SCC, MST with complete excision is 10-18 months; tonsillar SCC has a poorer prognosis (MST 6-8 months). For fibrosarcoma, MST is 8-12 months, with high local recurrence (50-70%) if margins are incomplete. In cats, oral SCC has a grave prognosis (MST 2-3 months) due to local invasion and poor response to therapy. Negative prognostic indicators include large tumor size (>2 cm), lymph node metastasis, distant metastasis, high histologic grade, and incomplete surgical margins. Positive prognostic indicators include early stage, complete excision, and non-tonsillar SCC.

Postoperative follow-up is essential. Suture removal: oral sutures are typically absorbable and do not require removal. Radiographic evaluation: thoracic radiographs every 3 months for the first year, then every 6 months for the second year, to monitor for pulmonary metastasis. Oral examination: monthly for the first 3 months, then every 3 months for the first year, to detect local recurrence. Activity restrictions: soft food diet for 2-4 weeks postoperatively, avoid hard toys or chews. Physical therapy: encourage gentle mouth opening exercises after healing. Long-term monitoring: annual bloodwork and imaging. Owners should be educated on signs of recurrence (e.g., bleeding, halitosis, difficulty eating).

Pearls: 1) Always perform a thorough oral examination under anesthesia, including palpation of the tongue and tonsils. 2) Use CT for surgical planning to assess bone invasion and tumor extent. 3) Obtain a biopsy before definitive surgery to guide treatment. 4) For mandibulectomy, preserve the contralateral mandible for stability. 5) Use a surgical margin of at least 1 cm, and submit the specimen for histologic margin evaluation. 6) Consider sentinel lymph node biopsy for accurate staging. 7) For cats with SCC, consider early euthanasia if surgical resection is not feasible due to poor prognosis. Pitfalls: 1) Incomplete excision due to inadequate margins, leading to recurrence. 2) Underestimating tumor extent without advanced imaging. 3) Failing to stage for metastasis, leading to inappropriate treatment. 4) Poor pain management, causing anorexia and weight loss. 5) Not addressing nutritional needs, especially in cats. 6) Overlooking the possibility of multiple primary tumors. 7) Using electrocautery excessively, which may compromise margin assessment.

Perioperative antimicrobial prophylaxis: Cefazolin 22 mg/kg IV at induction, repeated every 90 minutes during surgery. Postoperative antibiotics (e.g., amoxicillin-clavulanate 13.75 mg/kg PO q12h) for 7-10 days if contamination or infection is present. Analgesics: Preoperative: methadone 0.2-0.5 mg/kg IV or IM. Intraoperative: fentanyl CRI 5-10 mcg/kg/hr. Postoperative: hydromorphone 0.05-0.1 mg/kg IV q4-6h, or buprenorphine 0.01-0.02 mg/kg IV q6-8h. NSAIDs: carprofen 2.2 mg/kg PO q12h, or meloxicam 0.1 mg/kg PO q24h (dogs), 0.05 mg/kg PO q24h (cats). Local anesthesia: bupivacaine 1-2 mg/kg (max 2 mg/kg) as a nerve block (e.g., infraorbital, mandibular). Anti-emetics: maropitant 1 mg/kg IV or PO q24h if needed. Chemotherapy protocols: For melanoma: carboplatin 300 mg/m² IV q3 weeks for 4-6 cycles, or Oncept vaccine (0.1 mL intradermal q2 weeks for 4 doses, then q6 months). For SCC: mitoxantrone 5 mg/m² IV q3 weeks, or carboplatin 200 mg/m² IV q3 weeks. For fibrosarcoma: doxorubicin 30 mg/m² IV q3 weeks. Always adjust doses based on renal/hepatic function and monitor for myelosuppression.

Key studies: 1) Bergman et al. (2006) demonstrated that the Oncept melanoma vaccine significantly extended survival in dogs with stage II-III oral melanoma (MST 389 days vs 90 days for historical controls). 2) MacEwen et al. (1986) reported that surgery plus radiation therapy improved local control in canine oral melanoma compared to surgery alone. 3) Withrow et al. (2001) found that mandibulectomy for oral tumors resulted in a 1-year survival rate of 70% for SCC and 50% for melanoma. 4) The Veterinary Society of Surgical Oncology (VSSO) consensus guidelines recommend CT for staging and wide surgical excision with clean margins. 5) A study by Liptak et al. (2004) showed that incomplete margins are a significant negative prognostic factor for oral fibrosarcoma. 6) For feline oral SCC, a study by Hayes et al. (2007) reported a median survival of 2 months with surgery alone, emphasizing the need for early detection and aggressive multimodal therapy. 7) Recent meta-analyses support the use of sentinel lymph node mapping to improve staging accuracy. These studies underscore the importance of early diagnosis, complete surgical resection, and adjunctive therapies to improve outcomes.